Clinical Trials

Adenocarcinoma, Neoplasms

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

616 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07302347 2026-03-03

MK-3475-G21

20 enrolled

DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT05382559 2026-03-02

A Study of ASP3082 in Adults With Advanced Solid Tumors

681 enrolled

Neoplasm Metastasis, Neoplasms

NCT05920356 2026-02-27

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3 Recruiting

750 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

37 enrolled

Neoplasms, Recurrence

NCT06333951 2026-02-19

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

500 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

240 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05533697 2026-02-06

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07197827 2025-12-24

A Study of YL242 in Subjects With Advanced Solid Tumors

424 enrolled

Neoplasms

NCT05270213 2025-12-19

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

164 enrolled

Neoplasm Metastasis, Neoplasms

NCT05856981 2025-12-17

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicThoracic

130 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05859074 2025-12-03

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

DermatologicHead & NeckSarcoma

56 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Hemangiosarcoma, Melanoma, Neoplasm Metastasis, Neoplasms, Paget Disease, Extramammary, Sarcoma, Kaposi, Skin Neoplasms, Carcinoma, Merkel Cell, Adenocarcinoma, Sebaceous, Carcinoma, Skin Appendage

NCT06228326 2025-10-24

KYANITE-1

250 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07218003 2025-10-24

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

BreastGastrointestinalGenitourinaryGynecologicThoracic

149 enrolled

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05064280 2025-10-09

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Phase 2 Recruiting

104 enrolled

CNS

Brain Neoplasms, Neoplasms

NCT06983743 2025-09-11

AURORAS-1

200 enrolled

Neoplasm Metastasis, Neoplasms

NCT05359445 2025-09-09

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

95 enrolled

Neoplasms, Recurrence

NCT05378425 2025-09-09

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

90 enrolled

Neoplasm Metastasis, Neoplasms

NCT06031233 2025-05-21

MINUTE

Phase 4 Recruiting

679 enrolled

Neoplasms

NCT04787042 2024-11-15

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

BreastDermatologicGenitourinaryHead & NeckThoracic

316 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04510636 2024-03-22

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Phase 2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT06000358 2023-08-21

LUCACRIMUNO

Phase NA Recruiting

120 enrolled

GastrointestinalGynecologic

Lung Neoplasms, Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

24 enrolled

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

NCT05320588 2022-07-19

A Study in Patients With Advanced Cancers

332 enrolled